MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and ...
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (ATRC) (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, ...
The "AtriCure Inc (ATRC) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable ...
CFO Angie Wirick outlined the company’s early expectations for 2026 growth and discussed product adoption trends across its ...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...
Across the recent three months, 11 analysts have shared their insights on AtriCure (NASDAQ:ATRC), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their ...
Ratings for AtriCure (NASDAQ:ATRC) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results